Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement

Executive Summary

What was AstraZeneca's trash is now Ironwood's treasure, as it pays $100m up front, along with milestones and royalties, to acquire gout drug approved in December, but not yet launched.

Advertisement

Related Content

AZ's Gout Drug Gets FDA Go-Ahead With Safety Caveats
FDA: AZ/Ardea Gout Drug Modest Efficacy, Safety Concerns
AZ's lesinurad misses in Phase III gout at lower dose
AstraZeneca looks to combos after effective ex-Ardea drug shows serious adverse effects
AstraZeneca to pay $1.26 billion for Ardea and its gout product

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel